Share

April 28, 2009; 72 (17) Articles

PML-IRIS in patients with HIV infection

Clinical manifestations and treatment with steroids

K. Tan, R. Roda, L. Ostrow, J. McArthur, A. Nath
First published January 7, 2009, DOI: https://doi.org/10.1212/01.wnl.0000343510.08643.74
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
4962

Share

Abstract

Background: Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection that develops in immunosuppressed patients with HIV infection. Paradoxically, some of these patients may develop PML during combined antiretroviral therapy in the setting of immune reconstitution. We describe the types of PML in relation to immune reconstitution inflammatory syndrome (IRIS) and the effects of steroid use in these patients.

Methods: We performed a retrospective review of the literature (1998 to 2007) and of all HIV-infected patients diagnosed with PML-IRIS at Johns Hopkins Hospital (2004 to 2007). We recorded information on clinical features, microbiologic and virological analysis, neuroimaging, pathology, treatment, and outcome.

Results: Of 54 patients with PML-IRIS, 36 developed PML and IRIS simultaneously (PML-s-IRIS) and 18 had worsening of preexisting PML (PML-d-IRIS) after the initiation of combined antiretroviral therapy. PML-IRIS developed between 1 week and 26 months after initiation of antiretroviral therapy. PML-d-IRIS patients developed IRIS earlier, had higher lesion loads on MRI of the brain, had shorter durations of survival, and had higher mortality rate compared to PML-s-IRIS patients. Twelve patients received treatment with steroids, of which five died and seven showed good neurologic recovery. Patients who survived had received steroids early after IRIS diagnosis for longer durations and had contrast enhancement on IRIS neuroimaging.

Conclusions: Immune reconstitution following initiation of combined antiretroviral therapy may lead to activation of an inflammatory response to detectable or latent JC virus infection. Early and prolonged treatment with steroids may be useful in these patients but requires further investigation.

Glossary

FLAIR=
fluid-attenuated inversion recovery;
HAART=
highly active antiretroviral therapy;
IRIS=
immune reconstitution inflammatory syndrome;
JCV=
JC virus;
JHH=
Johns Hopkins Hospital;
PML=
progressive multifocal leukoencephalopathy;
PML-d-IRIS=
worsening of preexisting PML;
PML-s-IRIS=
PML and IRIS simultaneously.

Despite a dramatic decrease in the incidence of most opportunistic infections in the era of combined antiretroviral therapy, progressive multifocal leukoencephalopathy (PML) continues to occur at a similar frequency in patients with HIV infection. Up to 5% of patients with AIDS develop PML.1

This poses a unique challenge for the neurologist, because PML carries a high morbidity and mortality rate and for which there is no effective treatment. PML is caused by reactivation of JC virus (JCV), a polyomavirus, which infects oligodendrocytes and astrocytes in the CNS, inducing a non-inflammatory lytic reaction leading to demyelination, necrosis, and cell death.

The use of combined antiretroviral therapy markedly improves immune function and prognosis in HIV-infected patients2; however, PML may develop or worsen with antiretroviral therapy, despite a recovery of the immune system.3–25 This manifestation is believed to be a result of immune reconstitution inflammatory syndrome (IRIS).26 PML-IRIS may account for up to 18% of HIV-infected patients with PML.27 The lesions are often characterized by contrast enhancement on neuroimaging.4,6,8,11–13,15,18–22 Histopathologic examination demonstrates severe inflammatory and demyelinating lesions with marked infiltration by macrophages and CD8+ T lymphocytes.19

There are no evidence-based guidelines for the prevention or management of PML-IRIS. Some cases of IRIS are mild and resolve with continuation of combined antiretroviral therapy. Others result in significant morbidity and sometimes death. Anti-inflammatory agents such as steroids have been used and may be effective in the treatment of IRIS following other AIDS-related CNS infections.28 In this study, we examine the effects of steroid use in HIV-infected patients with PML-IRIS. We also contrast the features of patients who present with PML and IRIS simultaneously vs those whose neurologic deficits from PML worsened following the development of IRIS.

METHODS

We performed a retrospective analysis of HIV-infected patients diagnosed with PML-IRIS evaluated at Johns Hopkins Hospital (JHH) between April 2004 and October 2007. We also reviewed the published literature (1998 to 2007) for similar cases of patients with HIV who developed PML-IRIS at the onset or had worsening of neurologic symptoms following initiation of combined antiretroviral therapy as described by the authors. These patients either 1) were asymptomatic but developed new neurologic deficits due to PML and IRIS following combined antiretroviral therapy (PML-simultaneous-IRIS or PML-s-IRIS) or 2) already had existing PML with neurologic deficits, which worsened with the development of IRIS following initiation of combined antiretroviral therapy (PML-delayed-IRIS or PML-d-IRIS). We recorded information on clinical features, microbiologic and virologic analysis, neuroimaging, pathology, treatment, and outcome. Where data were lacking, the authors were contacted to obtain additional information.

PML-IRIS was defined by the following clinical criteria: 1) patient with HIV infection; 2) the diagnosis of PML was established by detection of JCV DNA in the CSF or brain tissue, characteristic histopathologic features in brain tissue, or by the presence of characteristic clinical and neuroradiologic features with exclusion of other opportunistic infections (tuberculosis, toxoplasmosis, cryptococcus, other viral infections) and CNS lymphoma; 3) treatment with combined antiretroviral therapy resulting in a decrease in plasma HIV viral load; 4) symptoms consistent with an infectious or inflammatory condition that appeared while the patient was on combined antiretroviral therapy; and 5) symptoms could not be explained by a newly acquired infection, the expected course of a newly diagnosed opportunistic infection, or drug toxicity.28

The extent of disease was determined by lesion load on MRI scan of the brain. A grading system was developed where one point was given for each affected brain region (frontal, temporal, parietal, occipital, deep gray nuclei, brainstem, and cerebellum) on each side. A good outcome was defined as survival with or without neurologic deficits and a poor outcome was defined as death from the condition at the time of report.

Statistical analysis.

Differences between groups were assessed using nonparametric Mann-Whitney test for continuous variables and Fisher exact test for differences in proportions. All statistical analyses were done with STATA version 10.2.

RESULTS

Case report.

A 66-year-old man with HIV infection diagnosed in 1991 and hepatitis C infection was restarted on antiretroviral therapy with darunavir, ritonavir, and Atripla (efavirenz, tenofovir, and emtricitabine) in August 2007. He had a CD4 cell count of 166 cells/mm3 and HIV plasma viral load of 193,379 copies/mL.

In October 2007, he presented to the hospital with progressive left hand weakness, hypophonia, and mild cognitive slowing. There was no fever, confusion, or other signs of systemic illness. He had a mild left hand weakness and clumsiness, left-sided hyperreflexia, and a left Babinski reflex.

Over the next few days, the patient developed a left hemiplegia. CSF analysis showed glucose of 61 mg/dL, protein of 57 mg/dL, 2 leukocytes, and 37 erythrocytes. CSF bacterial and fungal cultures and cryptococcal antigen were negative. Epstein Barr virus, herpes simplex virus 1 and 2, cytomegalovirus, and varicella zoster virus could not be detected by PCR. CSF JCV PCR was positive (50 copies/mL). At this stage, CD4 cell count was 376 cells/mm3 and HIV plasma viral load was 1,135 copies/mL. Brain MRI showed a hyperintense FLAIR lesion in the right motor strip, with mild gadolinium enhancement (figure 1A). MRI was of the spinal cord was unremarkable.

Figure

Figure 1 Axial FLAIR and contrast-enhanced brain MRIs in two patients

Axial fluid-attenuated inversion recovery (FLAIR) (A, B) and contrast-enhanced (C) brain MRI showing abnormal hyperintensity in the right motor strip (arrow in A). Seven weeks later, after completion of steroid treatment, there is enlargement of the contrast-enhanced lesion (B; arrowhead in C) despite clinical improvement. (D) Another patient with HIV infection and progressive multifocal leukoencephalopathy who had extensive patchy white matter involvement on an axial FLAIR image and (E) prominent contrast enhancement.

The patient was diagnosed with PML in the setting of an immune reconstitution inflammatory syndrome (PML-s-IRIS) and treated with 5 days of IV methylprednisolone (1 g/day) followed by a 6-week oral prednisone taper. His antiretroviral treatment regimen was maintained and he was also commenced on mefloquine (250 mg once weekly), which has been shown to have an inhibitory effect on JCV replication in vitro,29 which he has continued indefinitely. By day 4 of steroid treatment, the patient began to regain strength in his left arm and was discharged to a rehabilitation facility.

Six weeks later, the patient had residual left hemiparesis (upper extremity motor power grade 3/5 and lower extremity 4/5). His HIV plasma viral load had further decreased to 262 copies/mL and CD4 cell count was 335 cells/mm3. MRI showed enlargement of the right precentral gyrus lesion and new right frontal and temporal lesions, all of which enhanced with contrast (figure 1, B and C). To demonstrate the wide spectrum of contrast enhancement that may be seen with PML-IRIS, we have included the MRI of another patient with HIV infection and PML (JCV positive in CSF) who showed dramatic contrast enhancement (figure 1, D and E).

Characteristics of patients.

A total of 64 patients who fulfilled the clinical criteria for PML-IRIS were identified (4 from JHH; 60 from the literature).3–25 There were a total of 13 PML cases out of 2,816 HIV-infected patients treated with combined antiretroviral therapy in JHH over the same period (Richard Moore, personal communication). Nine of the patients described by De Luca et al.7 were excluded from the analysis because specific information was not reported and we were unable to obtain it from the authors. In one case series the diagnosis of PML was established by PCR for JCV in brain tissue only10; hence it is possible that the total number of PML cases may have been overestimated although the detection of JCV in normal brain tissue remains highly controversial. In one patient who was described twice in a case report and a subsequent case series,11,14 information from the case report was used in the analysis. Of the 54 patients included in the final analysis, 36 patients developed PML-s-IRIS and 18 patients had PML-d-IRIS after the initiation of antiretroviral therapy.

Relationship to initiation of antiretroviral therapy.

Antiretroviral therapy had been started at CD4 cell counts ranging between 0 and 450 cells/mm3 (median = 52.5; n = 46) and plasma HIV viral loads ranging between 3,372 and 1.3 × 106 copies/mL (median = 108,840; n = 38). IRIS was identified between 1 week and 26 months after treatment was initiated, with a median time of 7 weeks. The majority of patients (43/54; 80%) developed PML-IRIS within 12 weeks of initiation of combined antiretroviral therapy, but in 7 patients, PML-IRIS developed after 6 months of initiation of combined antiretroviral therapy (figure 2). Following initiation of combined antiretroviral therapy, CD4 cell counts increased at a median rate of 14.1 cells/mm3 per week (−6.8–528; n = 44), while HIV viral load decreased at a median rate of 19,838 copies/mL per week (141–258,840; n = 38) (table e-1 on the Neurology® Web site at www.neurology.org).

Figure

Figure 2 Time to onset of PML-s-IRIS and PML-d-IRIS after initiation of combined antiretroviral therapy

IRIS = immune reconstitution inflammatory syndrome; PML = progressive multifocal leukoencephalopathy; PML-d-IRIS = worsening of preexisting PML; PML-s-IRIS = PML and IRIS simultaneously.

There was no significant difference in the age, sex, CD4 cell counts, and HIV plasma viral loads prior to combined antiretroviral therapy and at onset of IRIS between PML-s-IRIS and PML-d-IRIS patients or their rates of change (table e-1). However, there was a trend for PML-d-IRIS patients to develop IRIS sooner after combined antiretroviral therapy initiation compared to PML-s-IRIS patients (4 weeks vs 8 weeks). PML-d-IRIS patients had a higher lesion load on MRI compared to PML-s-IRIS patients (mean [SD] = 3.27 [1.03] vs 2.0 [0.86], p = 0.001). PML-d-IRIS patients also had poorer outcomes compared to PML-s-IRIS patients. PML-d-IRIS patients had shorter overall durations of survival (2.5 weeks vs 8.5 weeks, p = 0.007) and died earlier (1 week vs 4.25 weeks, p = 0.003) compared to PML-s-IRIS patients. A greater proportion of PML-d-IRIS patients died from the condition compared to PML-s-IRIS patients (52.9% vs 31.3%) (table e-1).

Effect of treatment with steroids.

Twelve patients received treatment with steroids. There were no significant differences between patients treated with steroids and those not given steroids in their baseline characteristics of age, sex, CD4 cell counts and HIV plasma viral loads prior to combined antiretroviral therapy and at IRIS onset, the rate of change of CD4 cell counts and HIV plasma viral load, and time to PML-IRIS after initiation of antiretroviral therapy. With steroid treatment, there was no apparent difference in the duration of survival for all patients when only survivors were analyzed, or time to death for the patients who died (table 1).

View this table:

Table 1 Comparison of patients treated with steroids vs no steroids

When steroids were given, it was most often to treat catastrophic deterioration or when there was evidence of an inflammatory component of IRIS on neuroimaging. Although five patients died, seven patients showed good neurologic recovery with steroids use (table e-2). The characteristics of the seven patients who had good outcomes with steroids were compared to the five patients who had poor outcomes (table 2). While not significant, the following trends were noted: patients who survived had received steroids earlier after the recognition of IRIS (mean [SD] = 3 [1.4] vs 12.3 [17] weeks). They also received longer courses of steroids (mean [SD] = 13.3 [7.5] vs 3 [1.7] weeks) (6 months in case 4) and were tapered off steroids more slowly (cases 4 and 7). Patients who died despite steroid therapy were already severely ill when steroids were started (cases 9 and 12) or received steroids late in the course of IRIS (case 11) (table e-2).

View this table:

Table 2 Prognostic factors of patients with PML-IRIS treated with steroids

The MRI lesion load was similar between the patients treated with or without steroids (table 2). Six of the seven patients (85.7%) with good outcome had contrast enhancement on CT or MRI of the brain. Conversely, four of the five patients (80%) with poor outcome had no contrast enhancement on neuroimaging (table 2, table e-3).

DISCUSSION

IRIS is defined as paradoxical worsening of a patient’s clinical condition that is attributed to the recovery of the immune system after initiation of combined antiretroviral therapy.28 CNS manifestations of HIV-associated IRIS caused by mycobacteria, cryptococci, herpesvirus, cytomegalovirus, and JCV are increasingly being recognized.28,30 IRIS presenting during the early phase of combined antiretroviral therapy appears to reflect an immune response against an active or sometimes subclinical infection by opportunistic pathogens, whereas late IRIS may result from an immune response against the antigens of nonviable pathogens.28 In this article, we used a broad definition of PML-IRIS and included all patients who either developed PML after the initiation of HAART and a drop in HIV viral load or who experienced a progression of PML despite successful treatment with HAART. Using these criteria, it is assumed that the immune restoration may have contributed to the disease progression. However, it is also possible that the JCV infection may progress despite the immune restoration. Interestingly, cytokines under certain circumstances may activate JCV replication.

Factors predictive of development of IRIS include antiretroviral drug naivety, active or subclinical opportunistic infection at initiation of combined antiretroviral therapy, low CD4 count (<50 cells/mm3), and rapid immune recovery indicated by a prompt decrease in HIV plasma viral load.31 Higher baseline CD8 cell count, history of multiple opportunistic infections, and initiation of combined antiretroviral therapy in close proximity to the time of diagnosis of opportunistic infection may also be clinical predictors of IRIS.32 Genetic factors, such as polymorphisms in cytokine genes, have been implicated in IRIS initiated by herpesvirus and mycobacterial infections. These polymorphisms may impact the development of IRIS if they influence the clearance of the opportunistic pathogen before or after combined antiretroviral therapy, or if they exacerbate an immunopathologic response to the pathogen.33

The mechanisms leading to reactivation of JCV and the development of PML have not been entirely elucidated. After primary infection, JCV remains dormant in the kidneys, bone marrow, and lymphoid tissues.34 Reactivation of JCV in most cases occurs in the setting of profound cellular immunosuppression, leading to JC viremia. It is commonly thought that spread of JCV to the CNS occurs via the hematogenous route by white blood cells.25 On the other hand, although highly controversial, JCV DNA has also been found in the brain tissues of patients with AIDS without clinically evident PML35 as well as in normal individuals.36 Potential mechanisms of PML-IRIS development include an unraveling of a latent subclinical infection triggered by immune recovery or JCV-induced reactivation mediated by cytokines.26

Among this cohort of patients with PML-IRIS, there was no difference in the age, sex, or immunovirologic factors between PML-s-IRIS and PML-d-IRIS patients. Patients with PML-d-IRIS, however, progressed to IRIS over a shorter period compared to PML-s-IRIS patients. This may represent a priming of the immune system of PML-d-IRIS patients by exposure to preexisting JCV antigens, and thus requires a shorter duration to progress to the inflammatory stage of immune reconstitution. The poorer outcomes of PML-d-IRIS patients may be the result of a greater lesion load as seen on MRI of the brain from delayed recognition of IRIS as the initial neurologic deterioration may have been attributed to worsening of underlying PML.

The concept that treatment of an infectious agent can lead to an augmented immune response with paradoxical deterioration is well recognized in mycobacterium tuberculosis infections. Adjuvant steroid therapy in the treatment of tuberculous meningitis in HIV-negative patients improves survival.37 Steroids have been used and may be effective in IRIS following AIDS-related CNS infections caused by mycobacteria, cryptococci, and cytomegalovirus.28,30

Steroid treatment in PML-IRIS is anecdotal8,10,12,15,16,18,19,21 and treatment trials are lacking. The majority of PML-IRIS cases are characterized by mild symptoms and limited CNS inflammation. Some authors advocate use of steroids in IRIS when there is major neurologic worsening, clinical or radiologic evidence of swelling, mass effect, or brain herniation.26 The optimum time to institute steroid therapy, dose, and duration are not well established.28 Steroid therapy has been used safely in immunocompromised patients with HIV infection at low dosages for durations of up to 8 weeks.38 All the same, steroids should be used cautiously since experimental data suggest that it may increase the reservoir of HIV-infected cells.39

A major limitation of data collection from published literature is the availability of clinical information and the variation in data reporting. We obtained additional clinical data on the patients directly from the authors where necessary. We also ensured that all the cases fulfilled the clinical criteria for IRIS before inclusion for analysis. However, a drawback of this definition is that clinical deterioration could potentially occur from progression of the opportunistic infection despite immune reconstitution. In the absence of a surrogate marker for IRIS, this is still an acceptable operational definition.

Contrast enhancement is usually absent in classic PML lesions on MRI, and its presence is suggestive of development of an inflammatory response with breakdown of the blood–brain barrier. While contrast enhancement may potentially serve as a surrogate marker for IRIS, the contrast enhancement in patients with PML-IRIS was observed only in 56.7% (21 of 37). This could be because contrast enhancement in PML-IRIS may be subtle and can be missed by visual inspection of the scans, resulting in high interobserver variability. Hence, while contrast enhancement on neuroimaging would be helpful in the diagnosis of IRIS, its absence does not preclude it. For the purpose of this study we used the clinical definition of IRIS and included patients without contrast enhancement who clinically deteriorated after initiation of combined antiretroviral therapy but had an improvement in plasma HIV viral load and CD4 cell counts. Nonetheless, contrast enhancement in PML has been associated with a better prognosis.40 Consistent with this observation we found that 9 of the 20 patients with contrast enhancing lesions not treated with steroids had a good outcome. Interestingly, however, six of the seven patients who had contrast enhancing lesions and received steroids had a good outcome, suggesting that steroids may have further contributed to the improvement in clinical status.

Based on our series of patients with PML-IRIS, it is possible that some may benefit from treatment with steroids. However, the use of long-term steroids can only be resolved by formal studies on treatment in PML-IRIS. While necessary, these studies are difficult for several reasons: it is a sporadic phenomenon; there is no clear case definition; and some cases may resolve without any additional treatment other than combined antiretroviral therapy.

Footnotes

  • Embedded Image

  • Embedded Image

  • Supplemental data at www.neurology.org

    Editorial, page 1454

    e-Pub ahead of print on January 7, 2009, at www.neurology.org.

    Disclosure: The authors report no disclosures.

    Received July 3, 2008. Accepted in final form November 12, 2008.

REFERENCES

  1. ↵
    Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection: a review of the literature with a report of sixteen cases. Ann Intern Med 1987;107:78–87.
    OpenUrlCrossRefPubMed
  2. ↵
    Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999;52:623–625.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Sadler M, Chinn R, Healy J, Fisher M, Nelson MR, Gazzard BG. New treatments for progressive multifocal leukoencephalopathy in HIV-1-infected patients. Aids 1998;12:533–535.
    OpenUrlPubMed
  4. ↵
    Kotecha N, George MJ, Smith TW, Corvi F, Litofsky NS. Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 1998;105:541–543.
    OpenUrlCrossRefPubMed
  5. Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1999;28:1152–1154.
    OpenUrlAbstract/FREE Full Text
  6. Collazos J, Mayo J, Martinez E, Blanco MS. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 1999;13:1426–1428.
    OpenUrlCrossRefPubMed
  7. ↵
    De Luca A, Giancola ML, Ammassari A, et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 2000;182:1077–1083.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Miralles P, Berenguer J, Lacruz C, et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 2001;15:1900–1902.
    OpenUrlCrossRefPubMed
  9. Razonable RR, Aksamit AJ, Wright AJ, Wilson JW. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin Proc 2001;76:1171–1175.
    OpenUrlCrossRefPubMed
  10. ↵
    Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002;35:1250–1257.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Hoffmann C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003;74:1142–1144.
    OpenUrlAbstract/FREE Full Text
  12. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003;9 suppl 1:25–31.
    OpenUrlCrossRefPubMed
  13. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003;9 suppl 1:73–80.
    OpenUrlCrossRefPubMed
  14. Wyen C, Hoffmann C, Schmeisser N, et al. Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004;37:1263–1268.
    OpenUrlCrossRefPubMed
  15. Nuttall JJ, Wilmshurst JM, Ndondo AP, et al. Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J 2004;23:683–685.
    OpenUrlCrossRefPubMed
  16. Di Giambenedetto S, Vago G, Pompucci A, et al. Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? Neurology 2004;63:2452–2453.
    OpenUrlFREE Full Text
  17. Kastrup O, Wanke I, Esser S, Maschke M. Evolution of purely infratentorial PML under HAART–negative outcome under rapid immune reconstitution. Clin Neurol Neurosurg 2005;107:509–513.
    OpenUrlPubMed
  18. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005;109:449–455.
    OpenUrlCrossRefPubMed
  19. ↵
    Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005;11 suppl 3:16–22.
    OpenUrlCrossRefPubMed
  20. Wyen C, Lehmann C, Fatkenheuer G, Hoffmann C. AIDS-related progressive multifocal leukoencephalopathy in the era of HAART: report of two cases and review of the literature. AIDS Patient Care STDS 2005;19:486–494.
    OpenUrlCrossRefPubMed
  21. Martinez JV, Mazziotti JV, Efron ED, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006;67:1692–1694.
    OpenUrlAbstract/FREE Full Text
  22. Silva MT, Pacheco MC Jr, Vaz B. Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. Aids 2006;20:469–471.
  23. D’Amico R, Sarkar S, Yusuff J, Azar E, Perlman DC. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis 2007;39:347–350.
    OpenUrlCrossRefPubMed
  24. Imamura E, Yamashita H, Fukuhara T, et al. [Case of highly active anti-retroviral therapy-induced immune reconstitution inflammatory syndrome in AIDS-related progressive multifocal leukoencephalopathy.] Rinsho Shinkeigaku 2007;47:650–656.
    OpenUrlPubMed
  25. ↵
    Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006;60:162–173.
    OpenUrlCrossRefPubMed
  26. ↵
    Lima MA, Koralnik IJ. New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol 2005;11 suppl 3:52–57.
    OpenUrlPubMed
  27. ↵
    Cinque P, Pierotti C, Vigano MG, et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001;7:358–363.
    OpenUrlCrossRefPubMed
  28. ↵
    Riedel DJ, Pardo CA, McArthur J, Nath A. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol 2006;2:557–565.
  29. ↵
    Brickelmaier M, Lugovskoy A, Simon K, Gorelik L. Searching for novel therapeutics with anti-JCV activity among known bioactive drugs and experimental compounds. In:
  30. Shelburne SA, 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003;5:67–79.
    OpenUrlPubMed
  31. ↵
    Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids 2005;19:399–406.
    OpenUrlCrossRefPubMed
  32. ↵
    Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639–1646.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002;16:2043–2047.
    OpenUrlCrossRefPubMed
  34. ↵
    Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988;318:301–305.
    OpenUrlPubMed
  35. ↵
    Quinlivan EB, Norris M, Bouldin TW, et al. Subclinical central nervous system infection with JC virus in patients with AIDS. J Infect Dis 1992;166:80–85.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 2008 (in press).
  37. ↵
    Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741–1751.
    OpenUrlCrossRefPubMed
  38. ↵
    McComsey GA, Whalen CC, Mawhorter SD, et al. Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001;15:321–327.
    OpenUrlCrossRefPubMed
  39. ↵
    Wiegers K, Schwarck D, Reimer R, Bohn W. Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology 2008;375:73–84.
    OpenUrlPubMed
  40. ↵
    Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998;44:341–349.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Related Articles

Topics Discussed

Alert Me

Recommended articles